Physician profile
Karen E Beckman
NPI 1750384020
$1,237.12
in general payments reported to CMS, 2019-2025
16 companies · $96.50 in 2025
The $96.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $441 · 2021: $393 · 2022: $72.96 · 2023: $35.42 · 2024: $66.78 · 2025: $96.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.63 | 2020-2025 | |
| Welch Allyn | $375.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $119.80 | 2019 | |
| Novo Nordisk INC | $77.38 | 2020-2023 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $34.69 | 2025 | Watchman |
| Abbott Laboratories | $21.50 | 2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $20.76 | 2024 | Tirosint, Licart |
| Dexcom, INC. | $20.05 | 2021 | |
| Axonics, INC. | $19.12 | 2020 | |
| Allergan, INC. | $18.94 | 2020 | |
| Lilly USA, LLC | $18.69 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.33 | 2022 | |
| Astellas Pharma US INC | $15.07 | 2024 | Veozah |
| Amarin Pharma, INC. | $14.97 | 2022 | |
| Pfizer INC. | $13.23 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Beckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.